04:31 PM EDT, 04/28/2025 (MT Newswires) -- Kane Biotech ( KNBIF ) after trade Monday said it swung to a profit in the fourth quarter as its revenues doubled, while it also announced a narrowing in its strategic focus and a change in chief executive.

The company said it earned $227,321 in the fourth quarter, compared with a year-prior loss of $1.52 million.

Revenue for the quarter rose to $125,859 from $57,788 a year earlier. Fourth quarter revenue consists primarily of contract animal health manufacturing revenue for Dechra Veterinary Products.

In other news, the company said following completion of a recent review by its board, it decided to focus on the four verticals of its biofilm dispersion technology-based wound care product portfolio. "Management believes that the revyve product line, particularly in the U.S market, represents substantial opportunities for Kane," it added.

Kane also said chief executive Marc Edwards is no longer with the company. Dr. Robert Huizinga, currently Executive Chair, will serve as interim CEO. Prior to joining the company. Huizinga was the Executive Vice-President of Aurinia Pharmaceuticals. and led the clinical development of voclosporin which reached US$100 million in sales in year one. It noted Huizinga will resign from his position as Executive Chair at the upcoming annual meeting of shareholders in June. It gave no reasons for Edwards' departure.

The company's shares last traded Friday, closing at $0.095 on the TSX Venture Exchange